Long-term Outcomes Among Noncuratively Treated Men According to Prostate Cancer Risk Category in a Nationwide, Population-based Study

Rider, Jennifer R.; Sandin, Fredrik; Andrén, Ove; Wiklund, Peter; Hugosson, Jonas; Stattin, Pär

doi:10.1016/j.eururo.2012.08.001

Cited by 154 publications

(84 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prostate cancer is generally a disease of the elderly (70 years) and few men are diagnosed before the age of 50 years, the median age at being 68 years [3,4]. However, despite high incidence and mortality rates in the elderly, more studies suggest that the elderly are undertreated [5][6][7][8]. Recent guidelines state that age alone should not prelude patients from efficient treatment [9].…”

mentioning

confidence: 99%

Trends in prostate cancer in elderly in Denmark, 1980–2012

et al. 2016

View full text Add to dashboard Cite

mentioning

confidence: 99%

Trends in prostate cancer in elderly in Denmark, 1980–2012

et al. 2016

View full text Add to dashboard Cite

“…The course of the disease varies from entirely indolent to fatal even for organ-confined tumours [2]. Therefore, accurate and individual risk estimates based on patient and tumour characteristics are essential for treatment decisions.…”

Section: Introductionmentioning

confidence: 99%

TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy

et al. 2015

View full text Add to dashboard Cite

BACKGROUND Transient receptor potential cation channel, subfamily M, member 4 (TRPM4) messenger RNA (mRNA) has been shown to be upregulated in prostate cancer (PCa) and might be a new promising tissue biomarker. We evaluated TRPM4 protein expression and correlated the expression level with biochemical recurrence (BR) following radical prostatectomy (RP). MATERIAL AND METHODS The study included 614 patients who had undergone RP. TRPM4 immunohistochemical staining was performed on samples of benign tissue, tissue containing PIN glands and PCa tissue using a commercially available polyclonal antibody. Staining intensity was recorded by two independent observers using a four-tired semi-quantitative grading system (0, 1+, 2+, 3+) converted into H-scores. Interobserver agreement was calculated by linear weighted kappa statistics. The association between staining intensity and BR was analysed using the Kaplan-Meier estimator and uni-and multiple Cox proportional hazard regression models. RESULTS Significantly higher staining intensity was found in PCa glands compared to benign glands (p < 0.001). The concordance rate in TRPM4 staining intensities for benign, PIN and PCa tissue ranged from 86.0 to 91.5 %, corresponding to linear weighted kappa values of 0.566-0.789. After adjusting for patient and tumour characteristics, patients with a higher staining intensity in PCa glands compared to matched benign glands and an H-score equal to or above the median had an increased risk of BR (HR 1.79-2.62; p = 0.01-0.03 for the two observers) when compared to patients with a lower staining intensity. CONCLUSIONS TRPM4 protein expression is widely expressed in benign and cancerous prostate tissue, with highest staining intensities found in PCa. Overexpression of TRPM4 in PCa (combination of high staining intensity and a high H-score) is associated with increased risk of BR after RP.

show abstract

“…1 Standard curative therapies have traditionally included radical prostatectomy and whole-gland radiation therapy (external beam or brachytherapy). These procedures, although clinically effective, incur a significant risk of quality of life diminishing morbidity, including incontinence, impotence and rectal injury.…”

Section: Introductionmentioning

confidence: 99%

Focal magnetic resonance guided focused ultrasound for prostate cancer: Initial North American experience

Lindner

Ghai

Spensieri

et al. 2012

CUAJ

View full text Add to dashboard Cite

The treatment of low-risk prostate cancer is a common clinical dilemma between standard curative whole gland therapy (and its associated quality of life diminishing side effects) and active surveillance (and its low, but real, risk of progression). The goal of focal therapy in low-risk prostate cancer is to achieve the best balance between cancer control and maintenance of quality of life. Magnetic resonance-guided focused ultrasound (MRgFUS) surgery is a non-invasive thermal ablation method that integrates magnetic resonance imaging for target identification, treatment planning and closed-loop control of thermal deposition and focused ultrasound for thermal ablation of the tumour target. This novel transrectal system allows for tumour localization, targeting and monitoring of tumour target ablation in real time, while simultaneously preserving adjacent normal tissue thereby minimizing the side effects of standard curative surgical or radiation therapy. We report the first North American clinical experience of treatment of localized prostate cancer with focal MR-guided transrectal focused ultrasound (clinicaltrial.gov identifier NCT01226576).

show abstract

Long-term Outcomes Among Noncuratively Treated Men According to Prostate Cancer Risk Category in a Nationwide, Population-based Study

Cited by 154 publications

References 25 publications

Trends in prostate cancer in elderly in Denmark, 1980–2012

Trends in prostate cancer in elderly in Denmark, 1980–2012

TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy

Focal magnetic resonance guided focused ultrasound for prostate cancer: Initial North American experience

Contact Info

Product

Resources

About